



(12) **United States Patent**
Hooper et al.

(10) **Patent No.:** **US 6,451,309 B2**
(45) **Date of Patent:** **Sep. 17, 2002**

(54) **PROPHYLACTIC AND THERAPEUTIC
MONOCLONAL ANTIBODIES**

(75) Inventors: **Jay W. Hooper**, New Market; **Alan L. Schmaljohn**; **Connie S. Schmaljohn**, both of Frederick, all of MD (US)

(73) Assignee: **The United States of America as represented by the Secretary of the Army**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/781,124**

(22) Filed: **Feb. 9, 2001**

Related U.S. Application Data

(60) Provisional application No. 60/182,066, filed on Feb. 11, 2000.

(51) **Int. Cl.**⁷ **A61K 39/42**; A61K 39/275

(52) **U.S. Cl.** **424/147.1**; 424/232.1;
530/388.3

(58) **Field of Search** 424/147.1, 184.1,
424/199.1, 202.1, 204.1, 232.1, 141.1; 530/388.3;
436/548

(56) **References Cited**

PUBLICATIONS

Ichihashi et al., *Virology* (1996) vol. 220, No. 2 pp. 491–494.*

Wolffe et al, *Virology*, vol. 211, No. 1, pp. 53–63, 1995.*

Roper et al., *Journal of Virology*, vol. 70, No. 6, pp. 3753–3762, 1996.*

Isaacs et al., *Journal of Virology*, vol. 66, No. 12, pp. 7217–7224, 1992.*

Hooper, Schmaljohn and Schmaljohn, “DNA Immunization with the Vaccinia L1R and/or A33R Genes”, Abstract and poster presented to American Society for Virology, Jul. 1998; Abstract labeled P23–6 (1 page), and copies of each part of poster (22 pages total).

Hooper, Thompson, Schmaljohn and Schmaljohn, “DNA Vaccination Against Poxvirus Using Combinations of IMV and EEV Immunogens”, Abstract labeled W33–5 corresponding to talk given at American Society for Virology meeting Jul., 2000.

Sanderson et al., “The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles”, *J. Gen. Virol.*, Jan. 2000, 81 Pt. 1:47–58, PubMed Abstract from National Library of Medicine, NCBI(1 page).

Rodriguez et al., “Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus”, *J. Virol.*, Nov. 1985 56 (2):482–488, PubMed Abstract from National Library of Medicine, NCBI (1 page).

Meyer et al., “Identification of Binding Sites for Neutralizing Monoclonal Antibodies on the 14-kDa Fusion Protein of Orthopox Viruses”, Short Communication, *Virology* 200, 778–783 (1994).

Czerny and Mahnel, “Structural and functional analysis of orthopoxvirus epitopes with neutralizing monoclonal antibodies”, *J. Gen. Vir.* (1990) 71, pp. 2341–2352.

Vazquez and Esteban, “Identification of Functional Domain in the 14–Kilodalton Envelope Protein (A27L) of Vaccinia Virus”, *J. Virology*, Nov. 1999, vol. 73, No. 11, pp. 9098–9109.

Vazquez et al., “The Vaccinia Virus 14–Kilodalton (A27L) Fusion Protein Forms a Triple Coiled–Coil Structure and Interacts with the 21–Kilodalton (A17L) Virus Membrane Protein through a C–Terminal alpha–Helix,” *J. Virology*, Dec. 1998, vol. 72, No. 12, pp. 10126–10137.

Rodriguez et al., “The Vaccinia Virus 14–Kilodalton Fusion Protein Forms a Stable Complex with the Processed Protein Encoded by the Vaccinia virus A17L Gene”, *J. Virology*, Jun. 1993, vol. 67, No. 6, pp. 3435–3440.

Lai et al., “The Purified 14–Kilodalton Envelope Protein of Vaccinia Virus Produced in *Escherichia coli* Induces Virus Immunity in Animals”, *J. Virology*, Oct. 1991, vol. 65, No. 10, pp. 5631–5635.

Rodriguez and Esteban, “Mapping and Nucleotide Sequence of the Vaccinia Virus Gene that Encodes a 14–Kilodalton Fusion Protein”, *J. Virology*, Nov. 1987, vol. 61, No. 11, pp. 3550–3554.

Rodriguez et al., “Isolation and Characterization of Neutralizing Monoclonal Antibodies to Vaccinia Virus”, *J. Virol.*, Nov. 1985, vol. 56, No. 2, pp. 482–488.

Lin et al., “Vaccinia Virus Envelope H3L Protein Binds to Cell Surface Heparan Sulfate and is Important for Intracellular Mature Virion Morphogenesis and Virus Infection in Vitro and In Vivo”, *J. Virology*, Apr. 2000, vol. 74, No. 7, pp. 3353–3365.

Gordon et al., “A Prominent Antigenic Surface Polypeptide Involved in the Biogenesis and Function of the Vaccinia Virus Envelope”, *Virology* 181, pp. 671–686 (1991).

Ichihashi et al., “Identification of a Vaccinia Virus Penetration Protein”, *Virology* 202, pp. 834–843 (1994).

Demkowicz et al., “Identification and Characterization of Vaccinia Virus Genes Encoding Proteins that are Highly Antigenic in Animals and are Immunodominant in Vaccinated Humans”, *J. Virology*, Jan. 1992, vol. 66, No. 1, pp. 386–398.

* cited by examiner

Primary Examiner—Laurie Scheiner

(74) *Attorney, Agent, or Firm*—Elizabeth Arwine

(57) **ABSTRACT**

In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.